Berlin: (hib/STO) The CDU/CSU parliamentary group addresses the federal government’s “pharmaceutical strategy” in a small question (20/10901). In it, the parliamentary group writes that as a result of the ongoing supply bottlenecks for pharmaceuticals in Germany, the federal government presented a strategy paper on November 30, 2023 to “improve the framework conditions for the pharmaceutical sector in Germany – action concepts for the research and production location”. This should “make Germany more attractive again as a research and production location for the pharmaceutical industry”.
The MPs want to know what measures the federal government is planning to speed up the approval process for production facilities and the approval for the production of therapies. They also inquire about what effects “the tightening of penalties in the area of animal testing provided for in the draft bill for the Animal Protection Act have on achieving the goals of the pharmaceutical strategy”. They also ask, among other things, what risks could arise from the Federal Government’s perspective if, in cross-state research projects, the partners involved decide that a single data protection supervisory authority is solely responsible.